Ticker Details
X4 Pharmaceuticals Inc Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections.
IPO Date:	May 13, 2022
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.07 | 5.64%
Avg Daily Range (30 D):	$0.04 | 13.13%
Avg Daily Range (90 D):	$0.06 | 8.38%

Institutional Daily Volume
Avg Daily Volume:	1.66M
Avg Daily Volume (30 D):	45.64M
Avg Daily Volume (90 D):	16.53M

Trade Size
Avg Trade Size (Sh.):	278
Avg Trade Size (Sh.) (30 D):	680
Avg Trade Size (Sh.) (90 D):	628

Institutional Trades
Total Institutional Trades:	10
Avg Institutional Trade:	$.93M
Avg Institutional Trade (30 D):	$2.54M
Avg Institutional Trade (90 D):	$2.54M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	5

Market Closing Trades
Avg Closing Trade:	$.53M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	14.29K

News

Apr 10, 2026 @ 6:06 AM Why Actelis Networks Stock (ASNS) Crashed 33% Over... Source: Tanya Rawat

Mar 24, 2026 @ 1:10 PM Actelis Networks Announces Binding Term Sheet to A... Source: Globe Newswire

Mar 12, 2026 @ 8:24 AM Actelis Networks Declines Nearly 10% Following 48%... Source: Mohd Haider

Mar 4, 2026 @ 3:14 AM Actelis Networks (ASNS) Surges Over 55% After Hour... Source: Mohd Haider

Dec 18, 2025 @ 1:01 AM Actelis Networks Announces Pricing of $5 Million P... Source: Actelis Networks, Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-5.68	$-5.1	$-5.68
Diluted EPS	$-5.68	$-5.1	$-5.68
Revenue	$3.67M	$1.37M	$3.67M
Gross Profit	$1.22M	$.48M	$1.22M
Net Income / Loss	$-8.26M	$-2.52M	$-8.26M
Operating Income / Loss	$-7.19M	$-1.67M	$-7.19M
Cost of Revenue	$2.45M	$.89M	$2.45M
Net Cash Flow	$2.1M	$2.6M	$2.1M
PE Ratio

Splits
Nov 18, 2025	1:10
Apr 19, 2023	1:10
Mar 14, 2019	1:6